{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:05:06Z","timestamp":1784703906259,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universitat de Valencia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) represents a growing global health concern; however, its multiple pathogenic mechanisms remain incompletely understood. The role of the aryl hydrocarbon receptor (AHR) in MASLD is controversial, as it has been described as either pro- or anti-steatotic depending on the experimental context. Through whole-genome expression profiling and RT-qPCR analysis of human liver biopsies from two independent MASLD patient cohorts, we demonstrate that AHR expression and its canonical activity\u2014assessed by CYP1A1 mRNA levels\u2014are inversely correlated with hepatic steatosis. The role of AHR was further investigated in cultured human Upcyte\u00ae hepatocytes from different donors treated with a 2:1 oleate:palmitate mixture (0.6\u00a0mM) to induce steatosis, in combination with the exogenous AHR agonist \u03b2-naphthoflavone (BN, 25\u00a0\u00b5M) or the endogenous agonist 2-(1\u2032H-indole-3\u2032-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE, 25\u00a0\u00b5M). Activation of AHR resulted in a statistically significant reduction of intracellular lipid levels, as determined by triglyceride quantification and AdipoRed staining. Microarray analysis of AHR-activated human hepatocytes identified IGFBP1 as a robustly induced target gene. Consistently, IGFBP1 expression was diminished in the livers of both MASLD cohorts and positively correlated with AHR expression levels. Furthermore, treatment of human hepatocytes with recombinant IGFBP1, alone or in combination with IGF1, reduced lipid accumulation, supporting IGFBP1 as a potential downstream effector within the anti-steatotic AHR pathway. Collectively, these findings support a role for AHR and its target IGFBP1, as key negative regulators of hepatic lipid accumulation in human hepatocytes and suggest that activation of this pathway may be taken into account in the therapeutic approaches for MASLD.<\/jats:p>","DOI":"10.1007\/s00204-026-04513-w","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:16:27Z","timestamp":1784700987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The aryl hydrocarbon receptor is downregulated in MASLD while its activation attenuates steatosis in human hepatocytes through an IGFBP1-associated pathway"],"prefix":"10.1007","author":[{"given":"Marta","family":"del Pozo-Medina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Soluyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6684-8731","authenticated-orcid":false,"given":"Marta","family":"Moreno-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Jover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"4513_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ecl.2012.04.017","volume":"41","author":"DR Clemmons","year":"2012","unstructured":"Clemmons DR (2012) Metabolic actions of IGF-I in normal physiology and diabetes. Endocrinol Metab Clin North Am 41:425\u2013443. https:\/\/doi.org\/10.1016\/j.ecl.2012.04.017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"4513_CR2","doi-asserted-by":"publisher","first-page":"615S","DOI":"10.1093\/ajcn\/55.2.615s","volume":"55","author":"NI Consensus","year":"1992","unstructured":"Consensus NI (1992) Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. American J Clin Nutri 55:615S-619S. https:\/\/doi.org\/10.1093\/ajcn\/55.2.615s","journal-title":"American J Clin Nutri"},{"key":"4513_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.126263","volume":"251","author":"R Gui","year":"2023","unstructured":"Gui R, Li W, Li Z et al (2023) Effects and potential mechanisms of IGF1\/IGF1R in the liver fibrosis: a review. Int J Biol Macromol 251:126263. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.126263","journal-title":"Int J Biol Macromol"},{"key":"4513_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2337\/db16-0997","volume":"66","author":"NJ Haywood","year":"2016","unstructured":"Haywood NJ, Cordell PA, Tang KY et al (2016) Insulin-like growth factor binding protein 1 could improve glucose regulation and insulin sensitivity through its RGD domain. Diabetes 66:287\u2013299. https:\/\/doi.org\/10.2337\/db16-0997","journal-title":"Diabetes"},{"key":"4513_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME et al (2025) Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers 11:14. https:\/\/doi.org\/10.1038\/s41572-025-00599-1","journal-title":"Nat Rev Dis Primers"},{"key":"4513_CR6","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00204-017-1981-2","volume":"91","author":"SK Kolluri","year":"2017","unstructured":"Kolluri SK, Jin U-H, Safe S (2017) Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. Arch Toxicol 91:2497\u20132513. https:\/\/doi.org\/10.1007\/s00204-017-1981-2","journal-title":"Arch Toxicol"},{"key":"4513_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S et al (2025) Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open 8:e2454707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54707","journal-title":"JAMA Netw Open"},{"key":"4513_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1053\/j.gastro.2010.03.033","volume":"139","author":"JH Lee","year":"2010","unstructured":"Lee JH, Wada T, Febbraio M et al (2010) A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139:653\u2013663. https:\/\/doi.org\/10.1053\/j.gastro.2010.03.033","journal-title":"Gastroenterology"},{"key":"4513_CR9","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nbt.3377","volume":"33","author":"G Levy","year":"2015","unstructured":"Levy G, Bomze D, Heinz S et al (2015) Long-term culture and expansion of primary human hepatocytes. Nat Biotechnol 33:1264\u20131271. https:\/\/doi.org\/10.1038\/nbt.3377","journal-title":"Nat Biotechnol"},{"key":"4513_CR10","doi-asserted-by":"publisher","unstructured":"Marchand A, Tomkiewicz C, Marchandeau J-P, et al (2005) 2,3,7,8-Tetrachlorodibenzo-p-dioxin Induces Insulin-Like Growth Factor Binding Protein-1 Gene Expression and Counteracts the Negative Effect of Insulin. https:\/\/doi.org\/10.1124\/mol.104.004010","DOI":"10.1124\/mol.104.004010"},{"key":"4513_CR11","doi-asserted-by":"crossref","unstructured":"Marigota UM, Millet O, Lu SC, Mato JM (2024) Dysfunctional VLDL metabolism in MASLD | npj Metabolic Health and Disease. https:\/\/www.nature.com\/articles\/s44324-024-00018-1. Accessed 6 May 2026","DOI":"10.1038\/s44324-024-00018-1"},{"key":"4513_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/10408444.2015.1089471","volume":"46","author":"CL Mellor","year":"2016","unstructured":"Mellor CL, Steinmetz FP, Cronin MTD (2016) The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Crit Rev Toxicol 46:138\u2013152. https:\/\/doi.org\/10.3109\/10408444.2015.1089471","journal-title":"Crit Rev Toxicol"},{"key":"4513_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2131\/jts.33.405","volume":"33","author":"K Minami","year":"2008","unstructured":"Minami K, Nakajima M, Fujiki Y et al (2008) Regulation of insulin-like growth factor binding protein-1 and lipoprotein lipase by the aryl hydrocarbon receptor. J Toxicol Sci 33:405\u2013413. https:\/\/doi.org\/10.2131\/jts.33.405","journal-title":"J Toxicol Sci"},{"key":"4513_CR14","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1073\/pnas.0503488102","volume":"102","author":"B Oesch-Bartlomowicz","year":"2005","unstructured":"Oesch-Bartlomowicz B, Huelster A, Wiss O et al (2005) Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc Natl Acad Sci U S A 102:9218\u20139223. https:\/\/doi.org\/10.1073\/pnas.0503488102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4513_CR15","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1111\/jgh.15627","volume":"36","author":"J Pan","year":"2021","unstructured":"Pan J, Cen L, Zhou T et al (2021) Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 36:3438\u20133447. https:\/\/doi.org\/10.1111\/jgh.15627","journal-title":"J Gastroenterol Hepatol"},{"key":"4513_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/receptors2010001","volume":"2","author":"NY Patil","year":"2023","unstructured":"Patil NY, Friedman JE, Joshi AD (2023) Role of hepatic aryl hydrocarbon receptor in non-alcoholic fatty liver disease. Receptors 2:1\u201315. https:\/\/doi.org\/10.3390\/receptors2010001","journal-title":"Receptors"},{"key":"4513_CR17","doi-asserted-by":"publisher","first-page":"G433","DOI":"10.1152\/ajpgi.00337.2024","volume":"328","author":"NY Patil","year":"2025","unstructured":"Patil NY, Rus I, Ampadu F et al (2025) Cinnabarinic acid protects against metabolic dysfunction-associated steatohepatitis by activating aryl hydrocarbon receptor-dependent AMPK signaling. Am J Physiol Gastrointest Liver Physiol 328:G433\u2013G447. https:\/\/doi.org\/10.1152\/ajpgi.00337.2024","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4513_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/nu15143187","volume":"15","author":"\u00c1 P\u00e9rez-Rubio","year":"2023","unstructured":"P\u00e9rez-Rubio \u00c1, Soluyanova P, Moro E et al (2023) Gut microbiota and plasma bile acids associated with non-alcoholic fatty liver disease resolution in bariatric surgery patients. Nutrients 15:3187. https:\/\/doi.org\/10.3390\/nu15143187","journal-title":"Nutrients"},{"key":"4513_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep24740","volume":"6","author":"EM Pet\u00e4j\u00e4","year":"2016","unstructured":"Pet\u00e4j\u00e4 EM, Zhou Y, Havana M et al (2016) Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. Sci Rep 6:24740. https:\/\/doi.org\/10.1038\/srep24740","journal-title":"Sci Rep"},{"key":"4513_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169298","volume":"23","author":"G Quint\u00e1s","year":"2022","unstructured":"Quint\u00e1s G, Caiment F, Rienda I et al (2022) Quantitative prediction of steatosis in patients with non-alcoholic fatty liver by means of hepatic microRNAs present in serum and correlating with hepatic fat. Int J Mol Sci 23:9298. https:\/\/doi.org\/10.3390\/ijms23169298","journal-title":"Int J Mol Sci"},{"key":"4513_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/biom14111423","volume":"14","author":"P Soluyanova","year":"2024","unstructured":"Soluyanova P, Quint\u00e1s G, P\u00e9rez-Rubio \u00c1 et al (2024) The development of a non-invasive screening method based on serum microRNAs to quantify the percentage of liver steatosis. Biomolecules 14:1423. https:\/\/doi.org\/10.3390\/biom14111423","journal-title":"Biomolecules"},{"key":"4513_CR22","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","volume":"106","author":"TL Stanley","year":"2020","unstructured":"Stanley TL, Fourman LT, Zheng I et al (2020) Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 106:e520\u2013e533. https:\/\/doi.org\/10.1210\/clinem\/dgaa792","journal-title":"J Clin Endocrinol Metab"},{"key":"4513_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/toxsci\/kfs204","volume":"129","author":"R Tanos","year":"2012","unstructured":"Tanos R, Murray IA, Smith PB et al (2012) Role of the Ah receptor in homeostatic control of fatty acid synthesis in the liver. Toxicol Sci 129:372\u2013379. https:\/\/doi.org\/10.1093\/toxsci\/kfs204","journal-title":"Toxicol Sci"},{"key":"4513_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/toxsci\/kfw078","volume":"152","author":"L Tolosa","year":"2016","unstructured":"Tolosa L, G\u00f3mez-Lech\u00f3n MJ, L\u00f3pez S et al (2016) Human Upcyte hepatocytes: characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing. Toxicol Sci 152:214\u2013229. https:\/\/doi.org\/10.1093\/toxsci\/kfw078","journal-title":"Toxicol Sci"},{"key":"4513_CR25","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1016\/S0021-9258(20)81942-5","volume":"258","author":"KP Vyas","year":"1983","unstructured":"Vyas KP, Shibata T, Highet RJ et al (1983) Metabolism of alpha-naphthoflavone and beta-naphthoflavone by rat liver microsomes and highly purified reconstituted cytochrome P-450 systems. J Biol Chem 258:5649\u20135659. https:\/\/doi.org\/10.1016\/S0021-9258(20)81942-5","journal-title":"J Biol Chem"},{"key":"4513_CR26","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1074\/jbc.M115.693655","volume":"291","author":"T Wada","year":"2016","unstructured":"Wada T, Sunaga H, Miyata K et al (2016) Aryl hydrocarbon receptor plays protective roles against high fat diet (HFD)-induced hepatic steatosis and the subsequent lipotoxicity via direct transcriptional regulation of Socs3 gene expression. J Biol Chem 291:7004\u20137016. https:\/\/doi.org\/10.1074\/jbc.M115.693655","journal-title":"J Biol Chem"},{"key":"4513_CR27","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0504757102","volume":"102","author":"JA Walisser","year":"2005","unstructured":"Walisser JA, Glover E, Pande K et al (2005) Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. Proc Natl Acad Sci U S A 102:17858\u201317863","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4513_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cotox.2017.01.001","volume":"2","author":"EJ Wright","year":"2017","unstructured":"Wright EJ, Pereira De Castro K, Joshi AD, Elferink CJ (2017) Canonical and non-canonical aryl hydrocarbon receptor signaling pathways. Curr Opin Toxicol 2:87\u201392. https:\/\/doi.org\/10.1016\/j.cotox.2017.01.001","journal-title":"Curr Opin Toxicol"},{"key":"4513_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2024.153799","volume":"504","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Xu S, Liu J, Liu Z (2024) The effects of micro- and nanoplastics on the central nervous system: a new threat to humanity? Toxicology 504:153799. https:\/\/doi.org\/10.1016\/j.tox.2024.153799","journal-title":"Toxicology"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04513-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04513-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04513-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:16:28Z","timestamp":1784700988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-026-04513-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":29,"alternative-id":["4513"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04513-w","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}